DANVERS, Mass.--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that results from prophylactic use of the Impella 2.5 in complex coronary interventions from the USpella multicenter registry have been published in the December issue of the Catheterization and Cardiovascular Interventions Journal.
